

Attorney Docket No. 59572(46865)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Thomas J. JENTSCH

U.S.S.N.: 10/622,377

EXAMINER: Not yet assigned

FILED: July 18, 2003

GROÜP: Not yet assigned

FOR: TEST SYSTEM FOR THE DEVELOPMENT OF THERAPEUTIC AGENTS, IN

PARTICULAR, ACTIVE COMPOUNDS FOR THE TREATMENT OF

OSTEOPOROSIS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on **February 11, 2004**.

Patricia A Barnes

Date: February 11, 2004

COMMISSIONER FOR PATENTS P. O. BOX 1450 ALEXANDRIA, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.97 and 1.98; applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. <u>LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION</u>

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II.	COPIES								
	a. <u>X</u>	Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.							
	b <u>.</u>	This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application Serial No, filed on The following references were submitted to, and/or cited by, the Office in the prior application (s) and, therefore, are not required to be provided in this application.							
III.	CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)								
	a. <u>X</u>	Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).							
	b	A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:							
		ollowing additional information is provided for the Examiner's .deration:							
		<u>FEES</u>							
IV.	V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b) (check one box)								
	a	within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1]. No fee or certification is required.							
	b	within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2). No fee or certification is required.							

		c	X	Before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).			
	V.	BEING FILED UNDER 37 C.F.R. § 1.97(c): ox)					
		before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).					
		a		No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. §1.17(p).			
		b		or See the certification below. No fee is required.			
	CUNDER 37 C.F.R. § 1.97(e) (check only one box)						
	The u	ndersi	gned h	ereby states that			
		a		each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or			
		b		no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.			
	VI. The u	ndersiį	gned h	each item of information contained in the IDS was cited in communication from a foreign Patent Office in a counterpa foreign application not more than three months prior to the filing of this IDS; or no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpa foreign application or, to the best of my knowledge after ma reasonable inquiry, was known to any individual designate 37 C.F.R. § 1.56(c) more than three months prior to the filing	rt e rt aking d in		

,

Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of

Please charge Deposit Account No. 04-1105 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached.

X No fee is required.

this statement.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule, with a petition if necessary, and charge the appropriate fee to Deposit Account No. **04-1105**.

Respectfully submitted,

Date: 11 Flb 7004

Robert L. Buchanan Reg. No. 40,927

Attorney for Applicant(s)

EDWARDS & ANGELL, LLP P. O. Box 55874 Boston, MA 02205

Tel: (617) 439-4444

Fax: (617) 439-4170 / 7748

Customer No.: 21874

#433210

•			(g)								
FORM PTO)-144	9 FEB 1 3	2004 11	DOCKET NO:	SERIAL N	SERIAL NO.:					
		T DISCUSSIONES	. #	59572 (46865)	10/622,377						
INFORMA	TION	DISCLOSURES	TATEMENT	APPLICANT(S): Thomas	J. JENTSCH						
•				FILING DATE:	GROUP NO.:						
				July 18, 2003	Not yet assigned						
					<u> </u>		* ***				
UNITED STATES PATENT DOCUMENTS											
EXAM.		DOCUMENT					FILING DATE IF				
INITIALS		NUMBER	DATE	NAME	CLASS	SUBCLASS	APPROPRIATE				
	<u> </u>										
			3	FOREIGN PATENT DOCUM	IENTS						
		DOCUMENT					TRANSLATION				
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES/NO				
	BA	WO 00/24707	04/05/00	PCT							
	BB	WO 99/16909	08/04/99	PCT							
		OTHER DOCUM	IENTS (INCI	LUDING AUTHOR, TITLE, I	DATE, PER	TINENT PAC	GES, ETC.)				
	CA	CA Siike Brandt, Thomas J. Jentsch; CIC-6 and CIC-7 are two novel broadly expressed members of the CLC chloride channel family; Center for Molecular Neurobiology Hamburg (ZMNH), FEBS Letters 377 (1995) 15-20									
	СВ	Uwe Kornak, et al.; Complete genomic structure of the CLCN6 and CLCN7 putative chloride channel genes; Biochimica of Biophysica Acta 1447 (1999) 100-106									
•	CC	Erna Cleiren, et al.; Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutuations in the CICN7 chloride channel gene; Human Molecular Genetics, 2001, Vol. 10, No. 25 2681-2867									
	CD	Shinichi Uchida, et al.; Cloning and Expressionof a PKC-Regulated Chloride Channel; Japanese Journal of Physiology, 44, Suppl. 2, S55-S62, 1994									
	CE	Paul H. Schlesinger, et al.; Characterization of the Osteoclast Ruffled Border Chloride Channel and Its Role in Bone Resorption; The Journal of Biological Chemistry Vol. 272, No. 30, Issue of July 25, pp 18636-18643, 1997									
	CF	S.H.S. Pearce; Straightening out the renal tubule: advances in the molecular basis of the inherited tubulopathies; Q.J. Med 1998; 91:5-12									
	CG	Dayue Duan, et al.; Molecular identification of a volume-regulated chloride channel; Nature/Vol 390/27 November 1997									
	СН	Uwe Kornak, et al.; Loss of the CIC-7 Chloride Channel Leads to Osteopetrosis in Mice and Man; Cell, Vol. 104, 205-215, January 26, 2001, Copyright ©2001 by Cell Press, pp. 205-215									
	CI	CI Sandra M. Stobrawa, et al.; Disruption of CIC-3, a Chloride Channel Expressed on Synaptic Vesicles, Leads to a Loss of the Hippocampus; Neuron, Vol 29, 185-196, January, 2001, Copyright ©2001 by Cell Press, pp. 185-196									
	CJ	Nils Piwon, et al.; CIC-5 CI –channel disruption impairs endocytosis in a mouse model for Dent's disease; Nature Vol 408/16 November 2000, pp. 369-373									
	CK David Clapham; How to Lose Your Hippocampus by Working on Chloride Channels; Neuron, Vol. 29, 1-6, January, 2001, Copyright ©2001 by Cell Press, pp. 1-3										
EXAMINER	L:				DATE:	DATE:					

sheet 1 of 1